GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Telmisartan (ATC-Code nach WHO: C09CA07)

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 30, 2026
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient telmisartan (ATC code according to WHO: C09CA07)

This is one of 1,400 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedJuly 05, 2024
Procurement stageActive solicitation
Response dueSeptember 30, 2026
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 09, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Oxycodon und Naloxon (ATC-Code: N02AA55).
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-11 - Capsaicin (Darreichungsform: Pflaster)
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-33 - Propranolol (Darreichungsform: Lösung zum Einnehmen)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Bempedoinsäure + Ezetimib, (OBO) ATC C10BA10 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tacrolimus (ATC-Code nach WHO: D11AH01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Cinnarizin/Dimenhydrinat (ATC-Code nach WHO: N07CA52; amtlicher ATC: N07CA22)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Biperiden, ATC N04AA02
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Teriflunomid, ATC L04AK02 für die Zeit 01.10.2025 - 31.12.2025 (zzgl. Verlängerungsoption 1x12 Monate)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.